Pharmafile Logo
Pharmafocus logo
Advanced Search

Alzheimer’s disease

Showing 15 posts of 32 posts found.

milad-fakurian-58z17lnvs4u-unsplash_2

PharmaKure and Universiti Teknologi MARA (UiTM) partner for Alzheimer’s diagnosis research

December 13, 2023
Medical Communications Alzheimer's disease, Neurology, PharmaKure, UiTM

PharmaKure and the faculty of pharmacy at the University Teknologi MARA (UiTM), Malaysia, have announced a research collaboration focusing on …

News

Halozyme and Acumen Pharmaceuticals enter collaboration for Alzheimer’s treatment

November 7, 2023
Business Services Acumen Pharmaceuticals, Alzheimer's disease, Halozyme, Neurology, collaboration

Halozyme Therapeutics has announced a global collaboration and non-exclusive license with Acumen Pharmaceuticals, providing Acumen with access to Halozyme’s Enhanze …

News

Allyx Therapeutics shares phase 1a trial data for Alzheimer’s treatment

October 31, 2023
Medical Communications Allyx Therpeutics, Alzheimer's disease, Neurology, clinical trial

Allyx Therapeutics has announced phase 1a single ascending dose study results at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) …

News

Alnylam shares positive results from phase 1 trial

July 17, 2023
Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial

Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …

News
Alzheimer's brain

FDA grants Alzheimer’s disease drug Leqembi full approval

July 7, 2023
Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology

Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

May 5, 2023
Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …

News
394px-ad_versus_co

Eisai and Biogen’s Alzheimer’s drug slows progression in Phase 2 trials

July 26, 2018
Research and Development Alzheimer's disease, BAN2401, Biodgen, Eisai, phase 2, research

An experimental drug developed by the Massachusetts-based multinational Biogen and their Japanese partner Eisai has been shown to significantly slow …

News
hands-981400_960_720

Alzheimer’s protein treatment that works in human cells

April 12, 2018
Research and Development Alzheimer's disease, Gladstone Institutes, biotech, drugs, pharma, pharmaceutical

One of the major stumbling blocks that science has come up against, when trying to develop potential treatments for Alzheimer’s …

News
brain-1787622_640

Antiepileptic drug use linked to increased risk of Alzheimer’s and dementia

April 10, 2018
Manufacturing and Production, Research and Development Alzheimer's disease, dementia, epilepsy, pharma

A new study conducted at the University of Eastern Finland and the German Center for Neurodegenerative Diseases (DZNE) has revealed …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

February 16, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's disease, Roche, Top 10 news, Top ten news, Trump, biotech, drugs, pharma, pharmaceutical

Another week is finished and it’s been a disastrous one for research into a potential treatment for Alzheimer’s disease. Two of …

News
age

Diabetes drugs show potential in treating Alzheimer’s

January 3, 2018
Research and Development Alzheimer's disease, biotech, drugs, pharma, pharmaceutical

A group of researchers at Lancaster University have identified a drug currently used to treat type 2 diabetes that has …

News
blood-1813410_960_720

Blood test developed for early Alzheimer’s detection

July 20, 2017
Medical Communications, Research and Development Alzheimer's disease, biotech, drugs, pharma, pharmaceutical

A blood test has been created that could offer an inexpensive, and less invasive, alternative to current Alzheimer’s disease tests. …

News
tau_tangle

Atomic structure of tau revealed opening up new Alzheimer’s targets

July 6, 2017
Research and Development Alzheimer's disease, dementia, tau protein, tau tangle

It is a research breakthrough that has been touted as the biggest development in Alzheimer’s disease research for a quarter …

News
lilly2_web

Lilly forced to abandon Alzheimer’s drug after failed trial

November 24, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Alzheimer's disease, Eli Lilly

Eli Lilly announced that the results of its ‘Expedition 3’ trial for an experimental Alzheimer’s disease drug meant that they would …

News
astrazeneca_logo_building

FDA fast tracks Alzheimer’s drug from Lilly, AstraZeneca

August 22, 2016
Manufacturing and Production, Research and Development Alzheimer's disease, AstraZeneca, BACE, lilly, phase III

AstraZeneca and Eli Lilly have announced that the US Food and Drug Administration (FDA) has granted AZD3293 its fast track …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024